Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Invisalign System Labeling Is Approved By FDA

Align Technology, Inc. announced that the US FDA has cleared new labeling for the Invisalign system by removing the permanent dentition limitation from the indications for use. In addition, certain condition such as contraindication has been changed to precautions. "Over the years, our customers have demonstrated that many different types of malocclusion can be effectively treated with Invisalign," said Thomas M. Prescott, president and CEO. "Their clinical successes, along with our manufacturing and process improvements, have enabled us to amend our product labeling to reflect this broader applicability." "Today, doctors are offering Invisalign primarily to adults and teens. This change is an important step towards facilitating our long term goal of making Invisalign the preferred orthodontic treatment option for patients of all ages and for more severe types of malocclusion," said Dr. Eric Kuo, vice president of clinical technology. In 1998, the FDA cleared the Invisalign system that is used in patients with permanent teeth. The device is contraindicated for patients with mixed dentition, severe overbite, severe overjet, tooth malocclusion requiring surgical correction, adolescent patients with a skeletally narrow jaw and adult patients with dental prosthetics. The recently cleared labeling change was made based on a broader applications of the Invisalign system, advances in Align's manufacturing capabilities and advances in the current practice of orthodontic treatment that is being administered by doctors using the Invisalign system.